Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2020 · 10-Q
Revenue$1.76M$1.76M−39.8% vs Q1 2019 Net Income-$660.90K-$660.90KN/M vs Q1 2019 EPS Diluted-$0.02-$0.02N/M vs Q1 2019 Gross Profit$194,439−70.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$244,155N/M Free Cash Flowderived-$591,950N/M Margins · derivedGross margin11.0%−11.4 pt vs Q1 2019
Operating margin-34.0%−22.6 pt vs Q1 2019
Net margin-37.5%−23.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 14, 2020 · 44 d after period end